Department of Surgery, Breast Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J Surg Oncol. 2021 Mar;123(3):710-717. doi: 10.1002/jso.26287. Epub 2020 Nov 6.
Immunotherapy has been incorporated into the standard of care for a wide range of malignancies. The study of tumor-infiltrating lymphocytes has emphasized the importance of the host antitumor immune response in the natural history of breast cancer. Recent clinical trials have used immunotherapeutic approaches to augment this response and improve outcomes for patients with breast cancer. Here, we review several current clinical trial data that indicate checkpoint blockade may mediate clinically significant responses.
免疫疗法已被纳入多种恶性肿瘤的标准治疗方案。肿瘤浸润淋巴细胞的研究强调了宿主抗肿瘤免疫反应在乳腺癌自然史中的重要性。最近的临床试验已经使用免疫治疗方法来增强这种反应，并改善乳腺癌患者的预后。在这里，我们回顾了几项当前的临床试验数据，这些数据表明检查点阻断可能介导临床显著的反应。
